Hepatitis C

A review of more than 1,000 studies found the vast majority of economic analyses of HCV therapies don’t incorporate patient input.

Direct-acting antiviral sofosbuvir has had a high success rate in treating chronic HCV. But the potential for toxicity to the kidneys has raised some concern, especially in patients with CKD.

A triple combination of hepatitis C agents administered with another manufacturer's direct acting antiviral overcomes most difficult-to-cure Genotype 3.

Johnson & Johnson's pharmaceuticals company is discontiuing pursuits of triple-combination treatment JNJ-4178.

Researchers noted that some previous studies have found that sex hormones play a role in faster progression.

The vaccine is 75% to 95% effective in preventing perinatal hepatitis B transmission when given within 24 hours of birth, according to the AAP policy statement.

Scientists now have a clearer understanding of how the protein NS5A gets around the body’s cellular defenses.

An integrated care program successfully extended HCV treatment to patients not well served by traditional outreach efforts.

Researchers found in data of 1,868 people that women who inject drugs are at a 38% greater risk of contracting HCV than men who inject drugs.

The Section Head of Hepatology at the Cleveland Clinic discusses current issues in treating hepatitis, and what's still to come in possibly eradicating the disease.

Yuko Nagaoki and colleagues at Hiroshima University compared the occurrence of hepatocellular carcinoma in HCV patients cured with direct acting antivirals and those given interferon therapy.

An electronic health records prompt that reminds primary care providers to recommend testing has aided in an entire generations' lacking of hepatitis C screening, according to a new study.

The review is part of a multi-pronged effort to curb opioid abuse nationwide.

Poverty and poor healthcare raise the trending global risks.

A triple drug combination effectively cured patients with hepatitis C virus after they had failed to respond to a combination of two oral direct acting antivirals.

Neurotoxin EB-001's fast treatment start-up and shorter duration could make for a different focal pain reliever.

Sofosbuvir-based direct acting antiviral combinations for hepatitis C virus were found as effective and well tolerated in elderly patients as in younger populations.

The potential Hepatitis B adult vaccine has had a half-decade of rebuff to its drug application.

“This study tells us that the opioid epidemic has made people sicker and killed more people, in spite of all the care we can provide in the ICU, including mechanical ventilation, acute dialysis, life support and round-the-clock care."

Could US leaders in government and health care follow the same route?

In a 600-patient study, PCPs and NPs were shown to be just as effective as specialists in HCV treatment with direct-acting antivirals.

Within a week of a Presidential committee tasked with overseeing the epidemic, a study has shown national addiction drug death rates are understated.

The cost-effectiveness of curing hepatitis C virus relative to managing the chronic illness has been argued, and now pharmacoeconomic comparisons may have identified the most cost-effective treatment regimen.

The investigational hepatitis-B drug has been rejected for approval twice in the past 3 years, but creator Dynavax Technologies still hopes for an early 2018 US commercial release.

The fixed-dose combination therapy is an 8-week, once-daily treatment option for all HCV genotype diagnoses.

The device provides hybrid pulsed radio frequency waveforms that create electromagnetic effects, offering immediate chronic intractable pain relief.

RBP-6000, a injectable buprenorphine for adult moderate-to-severe OUD patients, was submitted for new drug application in May with major consideration to a phase 3 efficacy and safety study.

A form of the virus was isolated From New York City rats.

The sofosbuvir-based therapy was reviewed in a real-life Scandinavian study

HEPLISAV-B reported favorable marks for its lighter use — two doses every month — but was twice previously denied its marketing application in the past 3 years.